Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours

(2016) Holger Moch et al.   EUROPEAN UROLOGY

A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma

(2015) Ian J. Frew et al.   Annual Review of Pathology-Mechanisms of Disease

Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma

(2015) Jing Huang et al.   CHINESE MEDICAL JOURNAL

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

(2015) B. Beuselinck et al.   CLINICAL CANCER RESEARCH

International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality

(2015) Ariana Znaor et al.   EUROPEAN UROLOGY

BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies

(2015) Francesco Piva et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer

(2015) Lili Liao et al.   Cancer Genetics

An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma

(2014) Lucy Gossage et al.   HUMAN MOLECULAR GENETICS

Molecular Genetics of Clear-Cell Renal Cell Carcinoma

(2014) James Brugarolas   JOURNAL OF CLINICAL ONCOLOGY

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

(2014) Marco Gerlinger et al.   NATURE GENETICS

Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma

(2014) Mariana Rezende Alves et al.   VIRCHOWS ARCHIV

PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma

(2013) James Brugarolas   CANCER JOURNAL

Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network

(2013) A. A. Hakimi et al.   CLINICAL CANCER RESEARCH

Aberrant promoter hypermethylation ofPBRM1,BAP1,SETD2,KDM6Aand other chromatin-modifying genes is absent or rare in clear cell RCC

(2013) Ilsiya Ibragimova et al.   Epigenetics

Clinical and pathological impact ofVHL, PBRM1, BAP1, SETD2, KDM6A, andJARID1cin clear cell renal cell carcinoma

(2013) Lucy Gossage et al.   GENES CHROMOSOMES & CANCER

Pleiotropic Effects of the Trichloroethylene-Associated P81S VHL Mutation on Metabolism, Apoptosis, and ATM-Mediated DNA Damage Response

(2013) M. C. DeSimone et al.   JNCI-Journal of the National Cancer Institute

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

(2013) Payal Kapur et al.   LANCET ONCOLOGY

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression

(2013) Chunzhang Yang et al.   Cell Reports

The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1

(2012) Yanlai Lai et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

The VHL/HIF axis in clear cell renal carcinoma

(2012) Chuan Shen et al.   SEMINARS IN CANCER BIOLOGY

Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking?

(2012) Adriana von Teichman et al.   VIRCHOWS ARCHIV

Reliable detection of subclonal single-nucleotide variants in tumour cell populations

(2012) Moritz Gerstung et al.   Nature Communications

VHL Gene Mutations and Their Effects on Hypoxia Inducible Factor HIF : Identification of Potential Driver and Passenger Mutations

(2011) M. P. Rechsteiner et al.   CANCER RESEARCH

JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma

(2011) T Kanno et al.   ONCOGENE

von Hippel-Lindau-Dependent Patterns of RNA Polymerase II Hydroxylation in Human Renal Clear Cell Carcinomas

(2010) Y. Yi et al.   CLINICAL CANCER RESEARCH

Alterations in VHL as potential biomarkers in renal-cell carcinoma

(2010) Lucy Gossage et al.   Nature Reviews Clinical Oncology

The genetic basis of kidney cancer: a metabolic disease

(2010) W. Marston Linehan et al.   Nature Reviews Urology

Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma

(2009) A. C. Young et al.   CLINICAL CANCER RESEARCH

Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network

(2009) E. Leonardi et al.   FEBS LETTERS

VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

(2009) C. Lance Cowey et al.   Current Oncology Reports

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors

(2008) M. L. Nickerson et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

eEF1A Is a Novel Component of the Mammalian Nuclear Protein Export Machinery

(2008) Mireille Khacho et al.   MOLECULAR BIOLOGY OF THE CELL